The global lung cancer screening market was valued at $879.59 million in 2021, and is projected to reach $1,853.04 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
Lung cancer screening refers to methods for detecting early lung cancer before they cause symptoms at a point where they are more likely to be cured. Lung cancer is the most common type of cancer that begins in the lungs. Cigarette smoking is the main cause of lung cancer. Based on the microscopic appearance, the tumor cells are classified into small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC). The recommended screening test for lung cancer are low-dose computed tomography and X-ray.
The growth of global lung cancer screening market is majorly driven by alarming increase in prevalence of lung cancer across the globe, increase in smoking population, and technological innovations in screening methods. For instance, the American Society of Clinical Oncology (ASCO) in 2020, stated that the lung cancer is the 2nd most common type of cancer in women and men. In addition, rise in efforts taken by government for early stage detection of lung cancer propels the growth of the market.
Furthermore, rise in awareness regarding early stage screening for lung cancer and surge in the incidences of lung cancer are responsible to increase the demand for effective screening tests. These factors are expected to create growth opportunities for the lung cancer screening market during the forecast period.
However, high cost of screening tests and lack of awareness regarding screening techniques in the developing countries are the factors expected to hamper the growth of the market.
The lung cancer screening market is segmented into type, age group, end user, and region. By type, the market is categorized into low-dose computed tomography (LDCT) and X-ray. On the basis of age group, the market is segregated into 50 and older and below 50. By end user, the market is classified into hospitals, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global lung cancer screening market are Canon Medical Systems U. S. Inc., Eon Health, Fujifilm Holdings Corporation, General Electric Company (GE Healthcare), Koninklijke Philips N. V., Medtronic Plc, Microsoft Corporation (Nuance Communications, Inc. ), Penrad Technologies Inc., Siemens Ag, and Volpara Solutions Limited.
Lung cancer screening refers to methods for detecting early lung cancer before they cause symptoms at a point where they are more likely to be cured. Lung cancer is the most common type of cancer that begins in the lungs. Cigarette smoking is the main cause of lung cancer. Based on the microscopic appearance, the tumor cells are classified into small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC). The recommended screening test for lung cancer are low-dose computed tomography and X-ray.
The growth of global lung cancer screening market is majorly driven by alarming increase in prevalence of lung cancer across the globe, increase in smoking population, and technological innovations in screening methods. For instance, the American Society of Clinical Oncology (ASCO) in 2020, stated that the lung cancer is the 2nd most common type of cancer in women and men. In addition, rise in efforts taken by government for early stage detection of lung cancer propels the growth of the market.
Furthermore, rise in awareness regarding early stage screening for lung cancer and surge in the incidences of lung cancer are responsible to increase the demand for effective screening tests. These factors are expected to create growth opportunities for the lung cancer screening market during the forecast period.
However, high cost of screening tests and lack of awareness regarding screening techniques in the developing countries are the factors expected to hamper the growth of the market.
The lung cancer screening market is segmented into type, age group, end user, and region. By type, the market is categorized into low-dose computed tomography (LDCT) and X-ray. On the basis of age group, the market is segregated into 50 and older and below 50. By end user, the market is classified into hospitals, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global lung cancer screening market are Canon Medical Systems U. S. Inc., Eon Health, Fujifilm Holdings Corporation, General Electric Company (GE Healthcare), Koninklijke Philips N. V., Medtronic Plc, Microsoft Corporation (Nuance Communications, Inc. ), Penrad Technologies Inc., Siemens Ag, and Volpara Solutions Limited.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lung cancer screening market analysis from 2021 to 2031 to identify the prevailing lung cancer screening market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the lung cancer screening market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global lung cancer screening market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Low-dose computed tomography (LDCT)
- X-ray
By Age group
- 50 and older
- Below 50
By End User
- Hospitals
- Type
- Public
- Private
- Diagnostic Centers
- Others
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Canon Medical Systems Corporation
- Eon Health
- FUJIFILM Holdings Corporation
- General Electric incorporated (GE Healthcare)
- Koninklijke Philips N. V.
- Medtronic plc
- Nuance Communications, Inc.
- Penrad Technologies Inc
- Siemens AG (Siemens Healthineers AG)
- Volpara Solutions Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: LUNG CANCER SCREENING MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Low-dose computed tomography (LDCT)
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 X-ray
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: LUNG CANCER SCREENING MARKET, BY AGE GROUP
5.1 Overview
5.1.1 Market size and forecast
5.2 50 and older
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Below 50
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: LUNG CANCER SCREENING MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospitals Lung Cancer Screening Market by Type
6.2.4.1 Public Market size and forecast, by region
6.2.4.2 Private Market size and forecast, by region
6.3 Diagnostic Centers
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: LUNG CANCER SCREENING MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Age group
7.2.4 North America Market size and forecast, by End User
7.2.4.1 North America Hospitals Lung Cancer Screening Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Age group
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Age group
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Age group
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Age group
7.3.4 Europe Market size and forecast, by End User
7.3.4.1 Europe Hospitals Lung Cancer Screening Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Age group
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Age group
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Age group
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Age group
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Age group
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Age group
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Age group
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.4.1 Asia-Pacific Hospitals Lung Cancer Screening Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Age group
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Age group
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Age group
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Age group
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Age group
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Age group
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Age group
7.5.4 LAMEA Market size and forecast, by End User
7.5.4.1 LAMEA Hospitals Lung Cancer Screening Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Age group
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Age group
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Age group
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Age group
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Canon Medical Systems Corporation
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Eon Health
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 FUJIFILM Holdings Corporation
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 General Electric incorporated (GE Healthcare)
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Koninklijke Philips N. V.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Medtronic plc
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Nuance Communications, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Penrad Technologies Inc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Siemens AG (Siemens Healthineers AG)
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Volpara Solutions Limited
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Lung Cancer Screening Market,' the lung cancer screening market size was valued at $879.59 million in 2021, and is estimated to reach $1,853.04 million by 2031, growing at a CAGR of 7.7% from 2022 to 2031.The U.S. Preventive Services (USPSTF) recommends annual screening for lung cancer by using low-dose computed tomography (LDCT), in adults aged between 50-80 years who have a smoking history or currently smoke. Lung cancer occurs in people who consume tobacco, are exposed to asbestos, and due to family history of lung cancer. Lung cancer typically starts in the parts of lung, such as alveoli or bronchioles. Small cell lung cancer and non-small cell lung cancer are the two main types of lung cancer. In small cell lung cancer, malignant cells are small and round when observed under microscope. However, in non-small cell lung cancer, malignant cells are larger under a microscope. Thus, early stage screening for lung cancer may reduce the risks associated with the caner spread.
Factors that drive the growth of global lung cancer screening market include, increase in prevalence of non-small cell lung cancer, rise in obesity, lifestyle changes, and rise in smoking population that are more prone to develop lung cancer. For instance, according to the American Society of Clinical Oncology (ASCO), about 235,000 adults in U.S. were affected by lung cancer in 2020. In addition, technological innovations in screening methods and rise in R&D activities by market key players for developing advanced products contribute towards the growth of the lung cancer screening market share. Furthermore, increase in awareness regarding early stage screening and its benefits is the key factor expected to create lucrative growth opportunities for lung cancer screening market size during the forecast period.
However, lack of awareness and limited access to screening methods in low cost countries hampers the growth of the lung cancer screening industry.
Depending on type, the lung cancer screening market analysis is bifurcated into low-dose computed tomography (LDCT) and X-ray. The low-dose computed tomography (LDCT) exhibited the highest growth in 2021, and is expected to register fastest growth during the forecast period owing to increase in awareness about screening methods in developed countries and growing adoption of low-dose computed tomography in the screening of lung cancer.
On the basis of age group, the market is segmented into 50 and older and below 50. The 50 and older segment exhibited the highest growth in 2021, and is expected to register a fastest CAGR during the forecast, owing to rise in prevalence of non-small cell lung cancer in patients aged over 50.
On the basis of end user, the lung cancer screening industry is classified into hospitals, diagnostic centers, and others. The diagnostic centers segment dominated the market in 2021 and is expected to remain dominant during the forecast period. The market growth of this segment driven by growing preference of patients towards diagnostic centers for cancer screening. However, others segment expected to exhibit fastest growth during the forecast period, owing to adoption of cancer diagnostic equipment in cancer research institutes.
Region-wise, North America had the highest lung cancer screening market share in 2021, and is expected to maintain its lead during the forecast period, owing to growing cases of lung cancer and increase in adoption of technologically advanced screening solutions. Moreover, North America advances due to well established healthcare infrastructure. However, Asia-Pacific is expected to register a highest CAGR during the lung cancer screening market forecast period, owing to increasing smoking population and accessibility to advanced screening solutions in the healthcare facility.
KEY FINDINGS OF THE STUDY
By type, the low-dose computed tomography (LDCT) segment dominated the market in 2021.By age group, the 50 and older dominated the market in 2021, and is expected to continue this lung cancer screening market trends during the forecast period
By end user, the diagnostic centers dominated the market in 2021
Region-wise, North America generated the largest revenue share in 2021, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Canon Medical Systems Corporation
- Eon Health
- Fujifilm Holdings Corporation
- General Electric Incorporated (GE Healthcare)
- Koninklijke Philips N.V.
- Medtronic PLC
- Nuance Communications, Inc.
- Penrad Technologies Inc.
- Siemens AG (Siemens Healthineers AG)
- Volpara Solutions Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 271 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 879.59 million |
| Forecasted Market Value ( USD | $ 1853.04 million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
